<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017498</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-24982</org_study_id>
    <secondary_id>EORTC-24982</secondary_id>
    <nct_id>NCT00017498</nct_id>
  </id_info>
  <brief_title>Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck</brief_title>
  <official_title>Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who
      have recurrent or metastatic adenoid cystic cancer of the head and neck.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Assess the therapeutic activity of gemcitabine, in terms of objective response and
           duration of response, in patients with recurrent or metastatic adenoid cystic carcinoma
           of the head and neck.

        -  Determine the acute toxicity of this drug in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every
      21 days for a maximum of 12 courses in the absence of disease progression or unacceptable
      toxicity.

      Patients are followed every 12 weeks until disease progression and then every 6 months
      thereafter.

      PROJECTED ACCRUAL: A total of 16-29 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">21</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed metastatic or recurrent adenoid cystic carcinoma of the head
             and neck for which no curative options exist

               -  Symptomatic and/or progressive disease

          -  At least 1 unidimensionally measurable lesion

               -  At least 20 mm by conventional techniques OR

               -  At least 10 mm by spiral CT scan

               -  No bone metastases as only lesion

               -  Prior radiotherapy to only target lesion allowed if it has progressed or
                  reappeared after radiotherapy

          -  No CNS metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,500/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 10 g/dL

        Hepatic:

          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN) (2.5 times ULN if
             liver metastases present)

          -  AST or ALT less than 3 times ULN (5 times ULN if liver metastases present)

        Renal:

          -  Creatinine no greater than 1.7 mg/dL

        Other:

          -  No uncontrolled infection

          -  No concurrent serious systemic disorders that would preclude study

          -  No other prior or concurrent malignancy except:

               -  Adequately treated carcinoma in situ of the cervix

               -  Basal cell or squamous cell skin cancer

               -  Any malignancy that occurred more than 5 years ago with no symptoms or signs of
                  recurrence (except malignant melanoma, hypernephroma, or breast carcinoma)

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent immunotherapy

        Chemotherapy:

          -  No prior chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  No concurrent anti-estrogen therapy

          -  Concurrent steroid replacement or steroids as an antiemetic allowed

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 3 months since prior radiotherapy except for palliative radiotherapy to bone
             lesions

          -  No concurrent radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  At least 1 month since prior investigational agents

          -  No other concurrent experimental medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter H. M. de Mulder, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Medisch Centrum St. Radboud - Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>van Herpen CM, Locati LD, Buter J, Thomas J, Bogaerts J, Lacombe D, de Mulder P, Awada A, Licitra L, Bernier J, Vermorken JB. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer. 2008 Nov;44(17):2542-5. doi: 10.1016/j.ejca.2008.08.014. Epub 2008 Sep 24.</citation>
    <PMID>18819792</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>salivary gland adenoid cystic carcinoma</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

